Development and Optimization of Levofloxacin In-Situ Emulgel to Manage Ocular Bacterial Infections

    February 2025 in “ Notulae Scientia Biologicae
    Sidra Islam, Yashwant GIRI, Gurudutta Pattnaik
    Image of study
    TLDR Optimized emulgels with Levofloxacin effectively treat eye infections with prolonged drug release and safety.
    The study focused on developing and optimizing an in-situ emulgel containing Levofloxacin for managing ocular bacterial infections. Traditional eye drops often have poor bioavailability due to the eye's natural barriers, prompting the need for improved delivery systems. The researchers prepared various emulgels using different gelling agents and optimized them based on gelation time and capacity. Formulations F5, F9, F10, and F11 were identified as optimal, demonstrating prolonged drug release, enhanced residence time, and effective antibacterial action. These formulations were found to be biocompatible, suggesting they are safe and effective, and could potentially be used for delivering other antibiotics.
    Discuss this study in the Community →